Feng et al. demonstrate that high levels of glutamate are a characteristic of cancer. The METTL3/m6A/CD98 axis in cancer-associated fibroblasts promotes glutamate secretion, which in turn promotes the exhaustion of CD8+ T cells and inhibits the formation of immune memory. Targeting glutamate can sensitize neoadjuvant immunochemotherapy.